GPT and systemic inflammatory response syndrome: Five patients treated with sapanisertib plus TAK-117 discontinued due to treatment-related alanine aminotransferase increase, fatigue, general physical health deterioration, systemic inflammatory response syndrome, and transaminases increase (n = 1 each).